ArticleJournal of applied clinical medical physics2026
Same-day Hyaluronic Acid rectal spacer for TRUS-guided HDR Prostate Brachytherapy: Feasibility and dosimetric outcomes.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRectal spacers are widely used to reduce rectal dose in prostate radiotherapy. However, their use during transrectal ultrasound (TRUS)-guided high-dose-rate (HDR) brachytherapy has been limited by degradation of ultrasound image quality when placed on the day of the procedure, often necessitating CT-based planning or separate-day workflows. PURPOSE: To evaluate the feasibility and dosimetric impact of same-day hyaluronic acid (HA) rectal spacer injection in patients undergoing TRUS-guided HDR prostate brachytherapy.
methodsFollowing institutional review board approval, a retrospective analysis was performed on 20 patients with clinically localized prostate cancer treated with HDR brachytherapy combined with external beam radiation therapy between April 2023 and March 2024. Ten patients with a prostate-anterior rectal wall distance < 5 mm received HA rectal spacer injection immediately prior to HDR brachytherapy, while ten patients with a distance > 5 mm did not undergo spacer placement. HA spacer (3-6 cc) was injected into the perirectal space under sagittal TRUS guidance, followed by catheter placement and real-time TRUS-based treatment planning. A single fraction of 15 Gy was delivered. Dosimetric parameters were compared using an unpaired two-tailed Student's t-test.
resultsHA rectal spacer placement was technically successful in all patients (10/10) and preserved ultrasound image quality for catheter placement and treatment planning. Spacer placement improved prostate V100 (95.6% ± 0.5% vs. 94.5% ± 0.6%; p < 0.001) and significantly reduced rectal V75 (0.42 ± 0.25 cc vs. 0.97 ± 0.34 cc; p < 0.001). No significant differences were observed in urethral D10 or bladder D0.1cc.
conclusionsSame-day HA rectal spacer injection is feasible during TRUS-guided HDR prostate brachytherapy and preserves ultrasound image quality, enabling fully real-time treatment planning without the need for CT-based workflows. This approach provides rectal dose reduction while maintaining target coverage and may offer a streamlined alternative to multistep spacer placement strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.